Pneumonia in Post-Transplant Recipients

(Fishman's Pulmonary Diseases & Disorders | Murray & Nadel's Textbook of Respiratory Medicine)

1. Introduction and Why This Population is Unique

• They require more intensive immunosuppression than other SOT groups
• The transplanted organ is continuously exposed to the environment and respiratory secretions
• The bronchial anastomotic site has impaired blood supply, making it uniquely vulnerable
• Recipients with underlying cystic fibrosis arrive pre-colonized with multidrug-resistant (MDR) bacteria and fungi
• Prior colonizing organisms must guide both prophylaxis and empiric therapy

2. Timeline of Infections Post-Transplant (The "Net State of Immunosuppression")

3. Etiological Agents in Detail

A. Bacterial Pneumonia

• Gram-negative bacilli: Pseudomonas aeruginosa, Klebsiella, enteric gram-negatives
• Gram-positive: Staphylococcus aureus (including MRSA)
• Atypical: Mycoplasma, Legionella (in community-acquired presentations)
• Nocardia asteroides (presents as nodular or cavitatory lesion, often 1-6 months post-transplant)

B. Cytomegalovirus (CMV) Pneumonitis - Most Important Viral Cause

• CMV is the most common infectious cause of interstitial pneumonia in allogeneic bone marrow and solid organ transplant recipients
• Risk is greatest between day 30 and 90 post-transplant
• Late-onset CMV (>180 days) is increasingly recognized with effective prophylaxis
• Risk factors: D+/R- serostatus (seropositive donor, seronegative recipient), acute GVHD, intensive conditioning, allografts, advanced age
• In lung transplant recipients, CMV pneumonitis may precipitate bronchiolitis obliterans

1. Miliary pattern - focal lesions with cytomegaly, necrosis, alveolar hemorrhage, neutrophilic response
2. Interstitial pattern - alveolar cell hyperplasia, interstitial edema, lymphoid infiltration, diffuse cytomegalic cells

• Ganciclovir IV: 5 mg/kg every 12 hours (with dose adjustment for renal impairment) - drug of first choice
• Switch to oral valganciclovir 900 mg twice daily once clinical improvement occurs and the patient can tolerate oral medications
• CMV viral load monitored weekly to assess response and guide duration
• CMV immune globulin (previously recommended as adjunct in stem cell transplant) - recent studies show no clinical benefit
• Alternatives: Foscarnet (used for ganciclovir-resistant CMV) and cidofovir - both have serious side effects
• Newer agents: Maribavir and brincidofovir for refractory/resistant disease
• Prophylaxis: Letermovir (CMV terminase inhibitor) - approved for CMV-seropositive allogeneic HSCT recipients

C. Pneumocystis jirovecii Pneumonia (PCP)

• Progressive dyspnea, non-productive cough, fever
• Hypoxia disproportionate to auscultatory findings (key clinical clue - Fishman)
• Large alveolar-arterial oxygen gradient
• Elevated LDH
• Diffuse bilateral ground-glass opacities on CT

• Trimethoprim-sulfamethoxazole (TMP-SMX): 15-20 mg/kg/day of the trimethoprim component, in 3-4 divided doses IV for severe disease; switch to oral once improving
• Adjunctive corticosteroids for severe disease (PaO2 <70 mmHg or A-a gradient >35 mmHg): Prednisolone 40 mg BD x 5 days → 40 mg OD x 5 days → 20 mg OD x 11 days

• TMP-SMX (double strength) one tablet daily or one SS tablet daily - first line
• Alternatives: dapsone, aerosolized pentamidine, atovaquone (for sulfa-intolerant patients)
• Prophylaxis generally maintained for 6-12 months post-transplant

D. Invasive Aspergillosis (IA)

• Aspergillus fumigatus is the most common mold
• Occurs most commonly at 1-6 months post-transplant
• Risk factors: prolonged neutropenia, high-dose steroids, CMV co-infection
• CT: "Halo sign" (nodule with surrounding ground-glass halo) early; "Air-crescent sign" later with cavitation

• Voriconazole: Loading dose 6 mg/kg IV every 12 hours x 2 doses, then 4 mg/kg IV every 12 hours; oral: 200 mg every 12 hours - first-line therapy
• Therapeutic drug monitoring of voriconazole levels essential (narrow therapeutic index; extensive azole drug interactions with calcineurin inhibitors)
• Liposomal amphotericin B: 3-5 mg/kg/day IV - second line or combination
• Isavuconazole: 200 mg every 8 hours x 6 doses, then 200 mg daily - alternative to voriconazole
• Prophylaxis: Itraconazole, voriconazole, or posaconazole in high-risk patients

E. Mucormycosis

• Less common but rapidly progressive and life-threatening
• Presents as angioinvasive pulmonary infection with cavitation
• CT: subpleural mass with cavitation, reverse halo sign

• Liposomal amphotericin B: 5-10 mg/kg/day - first-line; must treat as medical emergency
• Surgical debridement is essential alongside medical therapy
• Isavuconazole or posaconazole as step-down or salvage

F. Other Organisms

• Nocardia: sulfamethoxazole-trimethoprim (high-dose) or imipenem; treat for 6-12 months
• Cryptococcus: Liposomal amphotericin B 3-4 mg/kg/day + flucytosine 100 mg/kg/day x 2 weeks (induction), then fluconazole 400 mg/day (consolidation)
• Endemic fungi (Histoplasma, Coccidioides, Blastomyces): itraconazole or amphotericin B depending on severity
• Respiratory viruses (influenza, RSV, parainfluenza, hMPV): prolonged and severe in transplant recipients; oseltamivir for influenza (75 mg BD x 5 days)

4. Diagnostic Approach (Fishman's Framework)

1. Bronchoscopy with BAL - gold standard for microbiological sampling
2. Molecular/PCR testing (CMV, PCP, respiratory viruses)
3. Serum biomarkers (galactomannan for Aspergillus, beta-D-glucan for fungi including PCP, cryptococcal antigen)
4. CT chest - pattern recognition guides differential:
   • Ground-glass: CMV, PCP, pulmonary edema
   • Nodules with halo: Aspergillus, CMV
   • Consolidation: bacterial, Nocardia
   • Cavitation: Aspergillus, Mucor, Nocardia, TB
5. Transbronchial or surgical lung biopsy when BAL non-diagnostic

5. Empiric Therapy Approach (Fishman, Ch. 123)

• Low risk: Narrow empiric coverage, maximize diagnostic yield before broadening
• High risk: Broad empiric coverage immediately; may need antibacterial + antiviral + antifungal simultaneously

• Hemodynamic status
• Oxygenation and pulmonary reserve
• Degree of neutropenia
• Severity of inflammatory response
• Net state of immunosuppression

6. Prophylaxis Strategy Post-Transplant

7. Special Considerations for Lung Transplant Recipients

1. Bronchial anastomotic infection (Fishman): early infection by Pseudomonas, S. aureus, and fungi - requires broad prophylaxis; debridement + aggressive antibiotics for treatment
2. Chronic lung allograft dysfunction (CLAD): BOS and restrictive allograft syndrome - respiratory viruses and CMV implicated; minimize exposure, vaccinate
3. Ureaplasma infection - associated with hyperammonemia syndrome post-lung transplant; requires specific culture/PCR for detection; treat with azithromycin or doxycycline
4. Reduction of immunosuppression as adjunct therapy - risky in lung transplant recipients as it can precipitate rejection; requires multidisciplinary decision
5. Immune reconstitution inflammatory syndrome (IRIS) - can occur on immunosuppression reduction; diagnosis of exclusion

Key Drug Dosage Summary Table

• Fishman's Pulmonary Diseases and Disorders, 5e - Chapters 123, 106 (Pulmonary Infection in Immunocompromised Hosts; Lung Transplantation)
• Murray & Nadel's Textbook of Respiratory Medicine, 7e - Chapter 46 (CMV and Viral Pneumonias), Chapter 125 (Transplant Recipients)